Statement re ARCHIMED

BioPharma Credit PLC

05 May 2026

 

5 May 2026

BIOPHARMA CREDIT PLC

(THE "COMPANY")

STATEMENT RE ARCHIMED ACQUISITION OF ESPERION THERAPEUTICS, INC.

The Company notes the announcement released on 1 May 2026 by Esperion Therapeutics, Inc. ("Esperion") regarding the entering into of a definitive agreement under which funds managed by ARCHIMED, an investment firm focused exclusively on healthcare industries ("ARCHIMED"), will acquire Esperion in a transaction valued at up to approximately US$1.1 billion in total equity value on a fully diluted basis, assuming full achievement of certain commercial-based milestones (the "Acquisition").

In connection with the Acquisition, the Company, along with BioPharma Credit Investments V (Master) LP, provided committed financing to ARCHIMED of up to USD$400 million, subject to customary closing conditions for the Acquisition.  The Company's allocation of such commitment will be between USD$78 to 120 million.  Esperion expects the Acquisition to close in the third quarter of 2026, subject to customary closing conditions, including approval by Esperion's shareholders and receipt of certain required regulatory approvals.  Since ARCHIMED is a privately held company, further details about the senior secured loan facility are not publicly available, but the terms of the loan are generally comparable with the Company's other investments.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

[phone]

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

[phone]

[e-mail]

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

END